Lipid DNA nanoparticles (NPs) exhibit an intrinsic affinity to the ocular surface and can be loaded by hybridization with fluorophore-DNA conjugates or with the anti-glaucoma drug travoprost by hybridizing an aptamer that binds the medication. In the travoprost-loaded NPs (Trav-NPs), the drug is bound by specific, non-covalent interactions, not requiring any chemical modification of the active pharmaceutical ingredient. Fluorescently labeled Trav-NPs show a long-lasting adherence to the eye, up to sixty minutes after eye drop instillation. Biosafety of the Trav-NPs was proved and in vivo. Ex vivo and in vivo quantification of travoprost via LC–MS revealed that Trav-NPs deliver at least twice the amount of the drug at every time-point investigated compared to the pristine drug. The data successfully show the applicability of a DNA-based drug delivery system in the field of ophthalmology for the treatment of a major retinal eye disease, i.e. glaucoma.

脂质DNA纳米颗粒（NPs）对眼表具有内在亲和力，可通过与荧光团DNA结合物或抗青光眼药物托沃前列素杂交（通过与药物结合的适体杂交）进行装载。在载有Travoprost的NP（Trav-NP）中，药物通过特定的非共价相互作用结合，不需要对活性药物成分进行任何化学修饰。荧光标记的Trav-NP在滴眼液后60分钟内对眼睛具有持久的附着力。Trav-NPs的生物安全性已得到证实并且在体内。通过的体内和体外定量travoprostLC-MS揭示，与原始药物相比，Trav-NP在每个研究的时间点上所输送的药物量至少是其两倍。数据成功地表明了基于DNA的药物递送系统在眼科领域用于治疗主要的视网膜眼病（即青光眼）的适用性。